Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

655
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
655

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.

Immunotherapy·2026
Same author

Molecular subtypes and lymph-node metastasis in endometrial cancer: An updated systematic review and meta-analysis.

Surgical oncology·2026
Same author

Complications of Temporary Transvenous Cardiac Pacing by Access Site: A Systematic Review and Meta-Analysis.

Pacing and clinical electrophysiology : PACE·2026
Same author

Publisher Correction: Reproducibility and robustness of economics and political science research.

Nature·2026
Same author

Reproducibility and robustness of economics and political science research.

Nature·2026
Same author

Fan Therapy for Dyspnea in Palliative and Supportive Care: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Respiratory care·2026

Related Experiment Video

Updated: Feb 18, 2026

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
07:14

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice

Published on: May 23, 2025

1.8K

KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future

Rafael Alvim Pereira1, Christian Oliveira2, Milena Tumelero3

  • 1Department of Medicine, Hospital Santa Casa, São José dos Campos, Brazil, raralvim5@gmail.com.

Oncology Research and Treatment
|February 16, 2026
PubMed
Summary

KRAS G12C inhibitors show promise for non-small cell lung cancer (NSCLC) brain metastases, but challenges remain. New strategies combining KRAS inhibitors with other therapies are being explored to improve outcomes for patients with central nervous system (CNS) involvement.

Keywords:
Brain metastasesCentral nervous system penetrationNon-small cell lung cancerTargeted therapy

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Surgical Transplantation of Tumor Cells into the Spinal Cord of Mice
05:39

Surgical Transplantation of Tumor Cells into the Spinal Cord of Mice

Published on: December 27, 2024

927

Related Experiment Videos

Last Updated: Feb 18, 2026

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
07:14

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice

Published on: May 23, 2025

1.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Surgical Transplantation of Tumor Cells into the Spinal Cord of Mice
05:39

Surgical Transplantation of Tumor Cells into the Spinal Cord of Mice

Published on: December 27, 2024

927

Area of Science:

  • Oncology
  • Pharmacology
  • Neuro-oncology

Background:

  • KRAS mutations, especially G12C, are common drivers in non-small cell lung cancer (NSCLC).
  • Brain metastases occur in up to 40% of advanced KRAS-mutant NSCLC patients, posing significant therapeutic challenges due to the blood-brain barrier.
  • Limited clinical data exists specifically addressing central nervous system (CNS) involvement in these patients.

Purpose of the Study:

  • To review the evolving role of KRAS-targeted therapies in NSCLC with CNS metastases.
  • To highlight recent clinical findings on KRAS G12C inhibitors like sotorasib and adagrasib.
  • To discuss challenges in achieving adequate drug penetration across the blood-brain barrier.

Main Methods:

  • Review of current clinical findings and literature on KRAS G12C inhibitors.
  • Analysis of resistance mechanisms to targeted therapies.
  • Exploration of novel combination strategies.

Main Results:

  • Adagrasib demonstrates promising intracranial activity and CNS penetration.
  • Key resistance mechanisms include bypass signaling, secondary KRAS mutations, and SHP2 feedback.
  • Combination strategies involving SHP2 inhibitors, immunotherapy, and radiation are under investigation.

Conclusions:

  • Brain metastases remain a significant challenge in KRAS-mutant NSCLC management despite treatment advancements.
  • Adagrasib shows potential for CNS-targeted therapy in NSCLC brain metastases.
  • Further research focusing on CNS-specific endpoints and integrated treatment approaches is crucial for patients with brain involvement.